Actuate Therapeutics, Inc. is a private biopharmaceutical company focused on the development of compounds for use in the treatment of cancer, and inflammatory diseases leading to fibrosis and neurodegeneration.
Actuate was founded in 2015 with a mission of discovering, developing, and commercializing new agents that target GSK-3β, based on intellectual capital developed in the laboratories of the University of Illinois-Chicago and Northwestern University. The company is led by a senior management and scientific team with decades of pharmaceutical industry experience leading successful discovery, development, and commercialization of new therapeutic agents and health related technologies.
We are currently advancing our lead molecule, 9-ING-41, towards the clinic in 2017. Our competitive analysis shows 9-ING-41 to be Best in Class. Ongoing research has demonstrated significant anti-tumor activity in many in vivo models of difficult to treat cancers, including cancers of the brain, pancreas, lung, and breast. We are unaware of any published research demonstrating the kind of efficacy in treatment-resistant glioblastoma that we have been able to achieve with 9-ING-41. Importantly, the toxicity and pharmacokinetic profiles of the drug candidate are quite attractive.